MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Arvinas Inc

Deschisă

SectorSănătate

9.5 3.26

Rezumat

Modificarea prețului

24h

Curent

Minim

9.18

Maxim

9.61

Indicatori cheie

By Trading Economics

Venit

-144M

-61M

Vânzări

-166M

22M

Marjă de profit

-273.214

Angajați

430

EBITDA

-144M

-72M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+120.71% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

77M

626M

Deschiderea anterioară

6.24

Închiderea anterioară

9.5

Sentimentul știrilor

By Acuity

50%

50%

149 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Arvinas Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 mai 2025, 18:41 UTC

Principalele dinamici ale pieței

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

Comparație

Modificare preț

Arvinas Inc Așteptări

Obiectiv de preț

By TipRanks

120.71% sus

Prognoză pe 12 luni

Medie 20.46 USD  120.71%

Maxim 110 USD

Minim 9 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArvinas Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

16 ratings

10

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

6.55 / 9.11Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

149 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
help-icon Live chat